Prevention of Serious Adverse Events Following Angiography (PRESERVE)
CSP #578 - Prevention of Serious Adverse Events Following Angiography (PRESERVE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Australian Capital Territory
-
Canberra, Australian Capital Territory, Australia, 2606
- Canberra Hospital
-
-
New South Wales
-
Concord, New South Wales, Australia, 2139
- Concord Hospital
-
Gosford, New South Wales, Australia, 2250
- Gosford Hospital
-
Kingswood, New South Wales, Australia, 2747
- Nepean Hospital
-
Kogarah, New South Wales, Australia, 2217
- St. George Hospital
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Flinders Medical Centre
-
-
Victoria
-
Epping, Victoria, Australia, 3076
- Northern Health
-
Heidelberg, Victoria, Australia, 3084
- Austin Health
-
-
Western Australia
-
Fremantle, Western Australia, Australia, 6160
- Fremantle Hospital
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital
-
-
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malaysia, 50603
- University of Malaya Medical Center
-
-
Pulau Pinang
-
George Town, Pulau Pinang, Malaysia, 10990
- Penang Hospital
-
-
Selangor
-
Sepang, Selangor, Malaysia, 43300
- Hospital Serdang
-
-
-
-
Auckland
-
Auckland, Auckland, New Zealand, 1142
- Auckland City Hospital
-
-
New Plymouth
-
Westown, New Plymouth, New Zealand, 4310
- Taranaki Base Hospital
-
-
Wellington Region
-
Newtown, Wellington Region, New Zealand, 1142
- Wellington Hospital
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85723
- Southern Arizona VA Health Care System, Tucson
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205-5484
- Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR
-
-
California
-
Palo Alto, California, United States, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
San Francisco, California, United States, 94121
- San Francisco VA Medical Center, San Francisco, CA
-
West Los Angeles, California, United States, 90073
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA
-
-
Florida
-
Bay Pines, Florida, United States, 33708
- Bay Pines VA Healthcare System, Pay Pines, FL
-
Gainesville, Florida, United States, 32608
- North Florida/South Georgia Veterans Health System, Gainesville, FL
-
-
Georgia
-
Augusta, Georgia, United States, 30904
- Charlie Norwood VA Medical Center, Augusta, GA
-
Decatur, Georgia, United States, 30033
- Atlanta VA Medical and Rehab Center, Decatur, GA
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Jesse Brown VA Medical Center, Chicago, IL
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-2884
- Richard L. Roudebush VA Medical Center, Indianapolis, IN
-
-
Massachusetts
-
West Roxbury, Massachusetts, United States, 02132
- VA Boston Healthcare System West Roxbury Campus, West Roxbury, MA
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48113
- VA Ann Arbor Healthcare System, Ann Arbor, MI
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417
- Minneapolis VA Health Care System, Minneapolis, MN
-
-
Missouri
-
Kansas City, Missouri, United States, 64128
- Kansas City VA Medical Center, Kansas City, MO
-
St Louis, Missouri, United States, 63106
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87108-5153
- New Mexico VA Health Care System, Albuquerque, NM
-
-
New York
-
Buffalo, New York, United States, 14215
- VA Western New York Healthcare System, Buffalo, NY
-
New York, New York, United States, 10010
- Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Durham VA Medical Center, Durham, NC
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Cincinnati VA Medical Center, Cincinnati, OH
-
Cleveland, Ohio, United States, 44106
- Louis Stokes VA Medical Center, Cleveland, OH
-
Dayton, Ohio, United States, 45428
- Dayton VA Medical Center, Dayton, OH
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma City VA Medical Center, Oklahoma City, OK
-
-
Oregon
-
Portland, Oregon, United States, 97201
- Portland VA Medical Center, Portland, OR
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15240
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401-5799
- Ralph H. Johnson VA Medical Center, Charleston, SC
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Memphis VA Medical Center, Memphis, TN
-
-
Texas
-
Dallas, Texas, United States, 75216
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
Houston, Texas, United States, 77030
- Michael E. DeBakey VA Medical Center, Houston, TX
-
San Antonio, Texas, United States, 78229
- South Texas Health Care System, San Antonio, TX
-
-
Utah
-
Salt Lake City, Utah, United States, 84148
- VA Salt Lake City Health Care System, Salt Lake City, UT
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- Hunter Holmes McGuire VA Medical Center, Richmond, VA
-
Salem, Virginia, United States, 24153
- Salem VA Medical Center, Salem, VA
-
-
Washington
-
Seattle, Washington, United States, 98108
- VA Puget Sound Health Care System Seattle Division, Seattle, WA
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Planned elective or urgent coronary or non-coronary angiography with iodinated contrast media in which it is anticipated that there will be an interval of 3 hours between the identification of the indication for angiography and the time of the planned procedure.
- Pre-angiography eGFR <60 ml/min/1.73 m2 with diabetes mellitus or pre-angiography eGFR <45 ml/min/1.73 m2 with or without diabetes mellitus
- Ability to provide informed consent
Exclusion Criteria:
- Stage 5 chronic kidney disease (CKD) (eGFR <15 mL/min/1.73 m2)
- Currently receiving hemodialysis, peritoneal dialysis, continuous renal replacement therapy, or sustained low efficiency dialysis (SLED)
- Unstable baseline serum creatinine (SCr) (if known) at the time of angiography defined by an increase in SCr of 25% over the 3 days prior to angiography
Decompensated heart failure requiring any of the following therapies at the time of angiography:
- IV milrinone, amrinone, dobutamine, or nesiritide
- Isolated ultrafiltration therapy
- Intra-aortic balloon pump
- Emergent angiography procedures defined as an anticipated duration of <3 hours between the identification of the indication for angiography and the time of the planned procedure.
- Receipt of intravascular iodinated contrast within the 5 days preceding angiography
- Receipt of oral or IV NAC within the 48 hours preceding angiography
- Known allergy to N-acetylcysteine (NAC)
- Known anaphylactic allergy to iodinated contrast media
- Prisoner
- Age <18 years
- Pregnancy
- Ongoing participation in an unapproved concurrent interventional study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Saline & oral placebo
IV isotonic saline and oral placebo drug capsule
|
The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour.
Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
|
|
Active Comparator: Saline & oral N-acetylcysteine
IV isotonic saline and oral N-acetylcysteine drug capsule
|
The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour.
Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
Other Names:
|
|
Active Comparator: Bicarbonate & oral placebo
IV isotonic bicarbonate and oral placebo drug capsule
|
A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour.
Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
|
|
Active Comparator: Bicarbonate & oral N-acetylcysteine
IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
|
NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
Other Names:
The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour.
Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Intravenous Sodium Bicarbonate With Intravenous Sodium Chloride.
Time Frame: Within 90 days following angiography
|
Death will be based on medical record and/or vital status registry documentation Need for acute dialysis will be defined as the initiation of any modality of renal replacement (intermittent hemodialysis, peritoneal dialysis, continuous renal replacement therapy, or sustained low-efficiency dialysis) Persistent decline in kidney function will be defined as an increase in serum creatinine of at least 50% from the baseline value collected pre-angiography to the measurement taken 90 days following the angiography.
|
Within 90 days following angiography
|
|
Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo.
Time Frame: Within 90 days following angiography
|
Death will be based on medical record and/or vital status registry documentation Need for acute dialysis will be defined as the initiation of any modality of renal replacement (intermittent hemodialysis, peritoneal dialysis, continuous renal replacement therapy, or sustained low-efficiency dialysis) Persistent decline in kidney function will be defined as an increase in serum creatinine of at least 50% from the baseline value collected pre-angiography to the measurement taken 90 days following the angiography.
|
Within 90 days following angiography
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Steven D. Weisbord, MD MSc, VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Heart Diseases
- Renal Insufficiency
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Myocardial Ischemia
- Acute Kidney Injury
- Coronary Artery Disease
- Kidney Diseases
- Amino Acids, Peptides, and Proteins
- Sulfur Compounds
- Organic Chemicals
- Inorganic Chemicals
- Chlorine Compounds
- Amino Acids
- Cysteine
- Amino Acids, Sulfur
- Sodium Compounds
- Chlorides
- Hydrochloric Acid
- Acetylcysteine
- Sodium Chloride
Other Study ID Numbers
Other Study ID Numbers
- 578
- 1011387 (Other Grant/Funding Number: National Health and Medical Research Council)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.